Immunome Announces Executive Shift, Welcomes New Accounting Officer
Company Announcements

Immunome Announces Executive Shift, Welcomes New Accounting Officer

Immunome (IMNM) has issued an update.

Bob Lapetina is set to depart from his executive roles at Immunome, Inc. on May 10, 2024, to explore new opportunities, leaving behind no company disputes. Following his exit, Max Rosett will step up as the new principal accounting officer. Bringing a diverse background, including a tenure at Morphimmune, Inc. and experience at Google and the Boston Consulting Group, Rosett’s appointment consolidates his financial leadership within Immunome, underlined by his recent role as Interim CFO and EVP of Operations. This strategic shift in the financial department signals continuous evolution in the company’s executive suite.

Learn more about IMNM stock on TipRanks’ Stock Analysis page.

Related Articles
Carrie WilliamsIMNM Earnings this Week: How Will it Perform?
TheFlyMolson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
TheFlyImmunome initiated with an Overweight at Stephens
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App